Table 3.
Characteristics of ankylosing spondylitis patients with cardiac conduction abnormalities according to conservative criteria; PQ-interval ≥ 220 ms and/or QRS complex ≥ 120 ms (n = 21)
|
Age |
Sex |
Symptom duration |
IVCD |
AV block |
BAS DAI |
BASFI |
BAS MI |
HLA B27 alleles |
Cardio-active Rx |
CVD |
|---|---|---|---|---|---|---|---|---|---|---|
| PM | ||||||||||
| 30 |
m |
8 |
LAFB |
|
5.76 |
3.2 |
3 |
1 |
0 |
|
| 38 |
m |
18 |
|
AV I |
2.99 |
1.34 |
1.6 |
1 |
0 |
|
| 43 |
m |
14 |
LBBB |
|
1.95 |
1.07 |
1.4 |
1 |
0 |
|
| 50 |
m |
27 |
|
AV I |
5.03 |
3.45 |
2.8 |
1 |
0 |
|
| 52 |
m |
13 |
|
AV I |
3.9 |
2.43 |
2 |
1 |
0 |
HT |
| 57 |
m |
33 |
RBBB |
AV I |
3.4 |
2.3 |
3.4 |
1 |
0 |
Valve disease |
| LAFB | ||||||||||
| 59 |
m |
36 |
LAFB |
|
1 |
0.9 |
5.6 |
1 |
0 |
|
| 61 |
m |
34 |
|
AV I |
1 |
1 |
1.8 |
1 |
BB* |
HT |
| 62 |
m |
38 |
LAFB |
|
4.65 |
3.88 |
3.6 |
1 |
(BB) |
Valve disease, |
| CAD | ||||||||||
| 63 |
m |
36 |
LAFB |
|
1.38 |
3.69 |
7.2 |
1 |
0 |
HT |
| 63 |
m |
49 |
|
AV I |
4.11 |
4.26 |
6 |
1 |
0 |
|
| 64 |
m |
45 |
LAFB |
|
0.89 |
2.36 |
6.8 |
1 |
0 |
Valve disease |
| 64 |
m |
44 |
LAFB |
|
2.34 |
2.53 |
7 |
1 |
(BB) |
AF; HT |
| 68 |
m |
39 |
LAFB |
|
3.44 |
4.99 |
4.2 |
0 |
0 |
Valve disease |
| 68 |
m |
42 |
RBBB |
|
5 |
4.56 |
5.6 |
1 |
0 |
Valve disease |
| HT | ||||||||||
| 71 |
m |
55 |
LAFB |
|
7.1 |
8.7 |
3.4 |
1 |
(BB) |
HT |
| 74 |
m |
25 |
LBBB |
|
NA |
NA |
6 |
1 |
(BB) |
Valve disease, |
| heart failure | ||||||||||
| 75 |
m |
52 |
|
PM |
3.84 |
6.65 |
7.2 |
1 |
(BB) |
Valve disease |
| HT | ||||||||||
| 77 |
m |
23 |
LAFB |
|
6.78 |
7.9 |
6.8 |
1 |
(BB) |
Valve disease |
| HT | ||||||||||
| 46 |
f |
39 |
|
AV I |
2.73 |
1.62 |
2.8 |
1 |
0 |
|
| 62 | f | 46 | LAFB | 3.57 | 3.09 | 3.2 | 2 | 0 |
Noted in the right hand column are substances that might affect atrio- and/or intra-ventricular conduction; when within brackets no clinical effect is assumed in the patient.
Abbreviations: AI aortic valve insufficiency, AV atrio-ventricular, AV I 1st degree AV block, BASDAI, BASFI, and BASMI1, see Table 2, BB beta-blocker, CAD coronary artery disease, CVD cardio-vascular disease, HT hypertension, IVCD intra-ventricular conduction disturbances, LAFB left anterior fascicular block, LBBB left bundle branch block, NA not available//missing data, PM pacemaker, RBBB right bundle branch block.
* beta-blocker therapy might impair atrio-ventricular but not intra-ventricular conduction.